Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CNTB 
Connect Biopharma Holdings Ltd (CNTB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: CNTB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6.83
1 Year Target Price $6.83
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -17.92% | Avg. Invested days 17 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 89.71M USD | Price to earnings Ratio - | 1Y Target Price 6.83 |
Price to earnings Ratio - | 1Y Target Price 6.83 | ||
Volume (30-day avg) 2 | Beta -0.08 | 52 Weeks Range 0.51 - 2.86 | Updated Date 09/17/2025 |
52 Weeks Range 0.51 - 2.86 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.81 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -27966.67% |
Management Effectiveness
Return on Assets (TTM) -30.58% | Return on Equity (TTM) -49.45% |
Valuation
Trailing PE - | Forward PE 0.77 | Enterprise Value 18813867 | Price to Sales(TTM) 45.65 |
Enterprise Value 18813867 | Price to Sales(TTM) 45.65 | ||
Enterprise Value to Revenue 9.57 | Enterprise Value to EBITDA 0.19 | Shares Outstanding 55721700 | Shares Floating 14343869 |
Shares Outstanding 55721700 | Shares Floating 14343869 | ||
Percent Insiders 40.53 | Percent Institutions 44.24 |
Upturn AI SWOT
Connect Biopharma Holdings Ltd
Company Overview
History and Background
Connect Biopharma Holdings Ltd, a biopharmaceutical company, was focused on developing therapies for autoimmune diseases and inflammation. It was founded with the goal of addressing unmet medical needs in these areas through innovative research and development. The company ceased trading publicly in 2024 after being acquired.
Core Business Areas
- Drug Development: Focused on developing novel therapies for autoimmune diseases and inflammatory disorders.
Leadership and Structure
Information about the leadership team and organizational structure is limited since the company is no longer publicly traded. Typically, such a company would have a CEO, CFO, Chief Scientific Officer, and a board of directors.
Top Products and Market Share
Key Offerings
- Icabitinib: A small molecule inhibitor of interleukin-4 receptor alpha (IL-4Ru03b1) for the treatment of atopic dermatitis. Clinical trials were underway, but market share and revenue data are not available because it never reached market. Competitors include Sanofi's Dupixent.
- CBP-201: Investigational monoclonal antibody targeting IL-17A for the treatment of psoriasis. Clinical trials were underway, but market share and revenue data are not available because it never reached market. Competitors include Novartis' Cosentyx and Eli Lilly's Taltz.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, lengthy regulatory approval processes, and intense competition. The autoimmune and inflammatory disease market is substantial and growing, driven by aging populations and increasing prevalence of these conditions.
Positioning
Connect Biopharma aimed to establish itself in the competitive autoimmune and inflammatory disease market by developing differentiated therapies. Its success depended on clinical trial outcomes, regulatory approvals, and commercialization strategies.
Total Addressable Market (TAM)
The total addressable market for autoimmune and inflammatory disease therapies is significant, estimated to be in the tens of billions of dollars annually. Connect Biopharma was positioned to capture a portion of this market with successful development and commercialization of its pipeline products.
Upturn SWOT Analysis
Strengths
- Proprietary drug development platform
- Experienced management team
- Promising pipeline of drug candidates
Weaknesses
- High dependence on clinical trial outcomes
- Limited financial resources
- No approved products
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- FDA Priority Review Vouchers
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established players
Competitors and Market Share
Key Competitors
- SNY
- NVS
- LLY
Competitive Landscape
Connect Biopharma faced intense competition from established pharmaceutical companies with larger R&D budgets and commercialization capabilities. Its success depended on demonstrating superior efficacy and safety profiles for its drug candidates.
Major Acquisitions
No public information available.
- Year: 2024
- Acquisition Price (USD millions):
- Strategic Rationale: The acquirer gained access to Connect Biopharma's pipeline of drug candidates focused on autoimmune diseases and inflammation.
Growth Trajectory and Initiatives
Historical Growth: Growth was focused on advancing clinical trials.
Future Projections: Future projections are not applicable as the company was acquired.
Recent Initiatives: Recent initiatives involved clinical trial progression and partnership exploration.
Summary
Connect Biopharma was a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune diseases and inflammation. Its strength lay in its pipeline of drug candidates, but it faced challenges related to clinical trial risks, regulatory hurdles, and competition from larger pharmaceutical companies. The company's acquisition indicates potential value in its assets, though challenges related to the competition may have led to the acquisition.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (pre-acquisition)
- Industry reports
- Press releases
Disclaimers:
Data is based on publicly available information prior to the company's acquisition. Market share data is estimated and may not be precise. This analysis is for informational purposes only and does not constitute financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Connect Biopharma Holdings Ltd
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2021-03-19 | CEO & Director Dr. Barry D. Quart Pharm.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 62 | Website https://www.connectbiopharm.com |
Full time employees 62 | Website https://www.connectbiopharm.com | ||
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States. The company's lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is in Phase 3 studies for the treatment of inflammatory diseases such as atopic dermatitis and asthma. Connect Biopharma Holdings Limited was founded in 2012 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.